M-VAX(TM) - a treatment for patients with advanced stage III melanoma
Medical Services Advisory Committee
Record ID 32003000110
English
Authors' objectives:
This report summarises the assessment of current evidence for M-VAX (TM) as a post-surgical adjuvant treatment of stage IIIB and IIIC melanoma.
Authors' recommendations:
MSAC recommended that on the strength of evidence pertaining to M-VAX(TM), a treatment for patients with advanced stage III melanoma, public funding should not be supported for this procedure.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.msac.gov.au/
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Costs and Cost Analysis
- Melanoma
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
Copyright:
Medical Services Advisory Committee (MSAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.